Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Key Inclusion Criteria:~* Willing and able to provide written informed consent~* Chronic HCV infection (≥ 6 months) documented by medical history or liver biopsy~* HCV genotype 4 at screening~* HCV treatment naive or prior participation in this study or study GS-US-334-0138 (Cohorts 1 and 2 only)~* Cohort 3 only: HCV treatment-experienced (previously received therapy for HCV infection with an interferon (IFN)-containing regimen, with or without RBV and/or an HCV NS3/NS4A protease inhibitor (PI)~* Body mass index (BMI) ≥ 18 kg/m\^2~* Screening laboratory values within defined thresholds~* Use of effective protocol-approved contraception methods~Key Exclusion Criteria:~* History of clinically-significant illness or any other major medical disorder that may interfere with treatment, assessment or compliance with the protocol~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Pregnant or nursing females or male with pregnant female partner~* Clinically-relevant drug or alcohol abuse within 12 months of screening~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF 8 wk TN (Cohort 1, Group 1) (Type: EXPERIMENTAL): LDV/SOF for 8 weeks (treatment-naive (TN))
- LDV/SOF+RBV 8 wk TN (Cohort 1, Group 2) (Type: EXPERIMENTAL): LDV/SOF+RBV for 8 weeks (treatment-naive)
- LDV/SOF 12 wk TN (Cohort 1, Group 3) (Type: EXPERIMENTAL): LDV/SOF for 12 weeks (treatment-naive)
- LDV/SOF+RBV 12 wk TN (Cohort 1, Group 4) (Type: EXPERIMENTAL): LDV/SOF+RBV for 12 weeks (treatment-naive)
- LDV/SOF+RBV 12 wk TE (Cohort 2) (Type: EXPERIMENTAL): Treatment-experienced (TE) participants who completed treatment in Gilead sponsored study GS-US-334-0138 or in Cohort 1 of this study and did not achieve SVR12 will receive LDV/SOF+RBV for 12 weeks.
- LDV/SOF 12 wk TE (Cohort 3, Group 1) (Type: EXPERIMENTAL): LDV/SOF for 12 weeks (treatment-experienced)
- LDV/SOF+RBV 12 wk TE (Cohort 3, Group 2) (Type: EXPERIMENTAL): LDV/SOF+RBV for 12 weeks (treatment-experienced)

Based on this trial design, predict the completion outcome and termination type (if applicable).